Reporting

• Adj. EBITDA of €578 m another 11% higher than already good Q1
• Reorganization program “Evonik Tailor Made” on track: ~€200 m cumulated cost savings already expected by end of FY 2025
• H1 FCF of €344 m more than €500 m above prior year
• Outlook range for adj. EBITDA materially lifted by €200 m to €1.9 to 2.2 bn

_{* The consensus is not controlled, changed or censored by Evonik Industries AG. Evonik Industries AG assumes no liability for the accuracy and completeness of these estimates and undertakes no obligation to update or revise such estimates and consensus data, even if they differ from Evonik Industries AG’s own forecasts or expectations. Evonik Industries AG is neither involved in the collection of the data, nor in the preparation of the consensus. This is done independently by Vara Research.}

• Adj. EBITDA of €522 m clearly above prior year (+28% yoy) – even despite limited macro support so far
• Drivers of strong Q1 performance: Nutrition & Care with Animal Nutrition and strong Care Solutions portfolio; Specialty Additives with strong operating leverage from volumes coming back
• Contingency & optimization measures further ramping up; preparation for €400 m “Evonik Tailor Made” savings on track
• FCF of €127 m well above prior-year quarter, based on improved earnings and continued tight NWC management
• Outlook range for adj. EBITDA (€1.7 to 2.0 bn) confirmed – Q2 adj. EBITDA expected on Q1 level

_{* The consensus is not controlled, changed or censored by Evonik Industries AG. Evonik Industries AG assumes no liability for the accuracy and completeness of these estimates and undertakes no obligation to update or revise such estimates and consensus data, even if they differ from Evonik Industries AG’s own forecasts or expectations. Evonik Industries AG is neither involved in the collection of the data, nor in the preparation of the consensus. This is done independently by Vara Research.}

• Q4 adj. EBITDA of €312 m to finish the year at €1,656 m and within outlook range (€1.6 to 1.8 bn) despite around -€50 m exceptional headwinds in Q4
• Update on reorganization program “Evonik Tailor Made”: Total savings of €400 m targeted by end of 2026
• FCF of €801 m stable yoy despite significant earnings decline, covering attractive & stable dividend proposal of €1.17
• FY 2024 adj. EBITDA outlook of €1.7 to 2.0 bn: Earnings growth enabled by cost savings and Animal Nutrition; Q1 already expected above prior-year level

_{* The consensus is not controlled, changed or censored by Evonik Industries AG. Evonik Industries AG assumes no liability for the accuracy and completeness of these estimates and undertakes no obligation to update or revise such estimates and consensus data, even if they differ from Evonik Industries AG’s own forecasts or expectations. Evonik Industries AG is neither involved in the collection of the data, nor in the preparation of the consensus. This is done independently by Vara Research.}

• Adj. EBITDA of €485 m well above Q2 level
• Weak economic environment offset by positive market momentum in Animal Nutrition and contingency support
• Contingency measures on track and to be extended into 2024
• Cash generation picking up strongly with FCF of €469 m in Q3
• Adj. EBITDA outlook for FY 2023 of €1.6 to 1.8 bn confirmed

_{* The consensus is not controlled, changed or censored by Evonik Industries AG. Evonik Industries AG assumes no liability for the accuracy and completeness of these estimates and undertakes no obligation to update or revise such estimates and consensus data, even if they differ from Evonik Industries AG’s own forecasts or expectations. Evonik Industries AG is neither involved in the collection of the data, nor in the preparation of the consensus. This is done independently by Vara Research.}

• Q2 adj. EBITDA of €450 m slightly better than Q1 (€409 m)
• Recovery slower than expected in May and June; persistently very weak demand across all end markets and continued customer destocking
• Strict contingency measures with supportive effect; on track to achieve full effect of €250 m in second half of the year
• Revised adj. EBITDA outlook for FY 2023 of €1.6 to 1.8 bn no longer assumes any recovery in H2
• FCF broadly stable in H1 (yoy) despite significantly weaker adj. EBITDA;
• FY target to develop cash conversion rate towards 40% confirmed

_{* The consensus is not controlled, changed or censored by Evonik Industries AG. Evonik Industries AG assumes no liability for the accuracy and completeness of these estimates and undertakes no obligation to update or revise such estimates and consensus data, even if they differ from Evonik Industries AG’s own forecasts or expectations. Evonik Industries AG is neither involved in the collection of the data, nor in the preparation of the consensus. This is done independently by Vara Research.}

• Q1 adj. EBITDA of only €409 m due to low volumes and despite positive pricing in Specialties; PA12 ramp-up driving Smart Materials, slow start in Specialty Additives, price pressure in Animal Nutrition and C4
• Through Q1 every month with sequentially better earnings – Start into Q2 continues on improved March level

• First divestment in Performance Materials: Divestment of Lülsdorf site signed; alkoxides business integrated into Smart Materials
• Strengthening competitiveness of Animal Nutrition business: Two separate operating models, with focus on efficiency and cost-leadership in amino acids
• Outlook FY 2023 confirmed: Lower end of adj. EBITDA range (€2.1 – 2.4 bn) more likely

_{* The consensus is not controlled, changed or censored by Evonik Industries AG. Evonik Industries AG assumes no liability for the accuracy and completeness of these estimates and undertakes no obligation to update or revise such estimates and consensus data, even if they differ from Evonik Industries AG’s own forecasts or expectations. Evonik Industries AG is neither involved in the collection of the data, nor in the preparation of the consensus. This is done independently by Vara Research.}